日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China

ARX788治疗HER2阳性乳腺癌脑转移患者的疗效和安全性(ACE-Breast-06):一项在中国开展的单臂II期临床试验

Li, Ting; Lin, Mingxi; Wang, Biyun; Zhao, Mingchuan; Cao, Jun; Wang, Leiping; Tao, Zhonghua; Jin, Juan; Miao, Haitao; Gong, Chengcheng; Zhao, Yannan; Peng, Wenxia; Hu, Xichun; Zhang, Jian

Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy

HER2超低表达乳腺癌的临床和基因组特征及其对T-DXd疗法的意义

Jin, Juan; Liu, Tiantian; Cai, Mengyuan; Zhao, Mingchuan; Guo, Duanchen; Lv, Hong; Wang, Leiping; Wang, Biyun; Wang, Hongxia; Tao, Zhonghua; Yang, Wentao; Hu, Xichun

Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China

转移性三阴性乳腺癌一线铂类化疗疗效预测列线图的构建与验证:基于中国五项前瞻性临床试验的患者水平分析

Gong, Chengcheng; Li, Ting; Chen, Yifan; Zhang, Jian; Zhao, Yannan; Wang, Leiping; Cao, Jun; Tao, Zhonghua; Zhao, Mingchuan; Hu, Xichun; Wang, Biyun

A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors

一项多中心、随机、双盲试验,比较生物类似药 LY01011 与地诺单抗 (Xgeva®) 在实体瘤骨转移患者中的疗效。

Zhao, Mingchuan; Hu, Xichun; Zhuang, Pengpeng; Zeng, Aiping; Yu, Yan; Chen, Zhendong; Sun, Hongmei; Yang, Weihua; Sheng, Lili; Peng, Peijian; Wang, Jingfen; Yi, Tienan; Bi, Minghong; Shi, Huaqiu; Ni, Mingli; Dai, Xiumei; Hu, Changlu; Xu, Hongjie; Lv, Dongqing; Li, Qingshan; Lei, Kaijian; Yuan, Xia; Jiang, Ou; Wang, Xicheng; Hu, Baihui; Hou, Zhe; Su, Zhaoping; Zheng, Song; Zhou, Ming; Dou, Changlin

Disulfidptosis and ferroptosis related genes define the immune microenvironment and NUBPL serves as a potential biomarker for predicting prognosis and immunotherapy response in bladder cancer

二硫代蛋白酶死亡和铁死亡相关基因定义了免疫微环境,NUBPL 可作为预测膀胱癌预后和免疫治疗反应的潜在生物标志物

Xuezhou Zhang, Baoan Hong, Hongwei Li, Zhipeng Sun, Jiahui Zhao, Mingchuan Li, Dechao Wei, Yongxing Wang, Ning Zhang

Basement membrane-related MMP14 predicts poor prognosis and response to immunotherapy in bladder cancer

基底膜相关 MMP14 预测膀胱癌预后不良和免疫治疗反应

Xuezhou Zhang #, Baoan Hong #, Hongwei Li #, Jiahui Zhao, Mingchuan Li, Dechao Wei, Yongxing Wang, Ning Zhang

Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer

HER2低表达乳腺癌的临床特征、基因组图谱和生存结果分析

Jin, Juan; Li, Bin; Cao, Jianing; Li, Ting; Zhang, Jian; Cao, Jun; Zhao, Mingchuan; Wang, Leiping; Wang, Biyun; Tao, Zhonghua; Hu, Xichun

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway

去势抵抗性前列腺癌的恩杂鲁胺耐药进展由 JAK2/STAT1 依赖性通路驱动

Yong Luo, Xiaobing Yang, Spyridon P Basourakos, Xuemei Zuo, Dechao Wei, Jiahui Zhao, Mingchuan Li, Qiankun Li, Tao Feng, Pengju Guo, Yongguang Jiang

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer

对表皮生长因子受体突变型肺癌中BIM缺失多态性对治疗结果影响的个体患者数据进行系统评价和荟萃分析

Soh, Sheila X; Siddiqui, Fahad J; Allen, John C; Kim, Go Woon; Lee, Jae Cheol; Yatabe, Yasushi; Soda, Manabu; Mano, Hiroyuki; Soo, Ross A; Chin, Tan-Min; Ebi, Hiromichi; Yano, Seiji; Matsuo, Keitaro; Niu, Xiaomin; Lu, Shun; Isobe, Kazutoshi; Lee, Jih-Hsiang; Yang, James C; Zhao, Mingchuan; Zhou, Caicun; Lee, June-Koo; Lee, Se-Hoon; Lee, Ji Yun; Ahn, Myung-Ju; Tan, Tira J; Tan, Daniel S; Tan, Eng-Huat; Ong, S Tiong; Lim, Wan-Teck

Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer

长链非编码RNA UCA1通过激活EGFR突变型非小细胞肺癌中的AKT/mTOR通路,诱导非T790M突变获得性EGFR-TKI耐药。

Cheng, Ningning; Cai, Weijing; Ren, Shengxiang; Li, Xuefei; Wang, Qi; Pan, Hui; Zhao, Mingchuan; Li, Jiayu; Zhang, Yishi; Zhao, Chao; Chen, Xiaoxia; Fei, Ke; Zhou, Caicun; Hirsch, Fred R